Prostate cancer is a neoplasm with a variable natural history and clinical behavior. There is much debate on the use of inherited genetic information in clinical application including risk assessment and treatment decisions. This study was performed to evaluate the relationship between clinical parameters of prostate cancer (PSA, Gleason score, and metastasis) and expression of NKX3.1, AMACR, TMPRSS2-ERG, ERG, and SPINK1 genes.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Newly diagnosed cases of prostate cancer were selected for this study. Thirty four tissue samples were obtained via open radical prostatectomy and 9 samples were obtained via needle biopsy. Each tissue sample was sectioned into two parts, one used for detection of malignant changes and Gleason score determination, and the other immersed in RNA later solution (Qiagen). The expression of NKX3.1, AMACR, TMPRSS2-ERG, ERG, and SPINK1 genes were assessed by real-time PCR assay. Correlation between expression of each gene and PSA level, Gleason score, and presence of metastasis were examined.
A total number of 43 specimens were studied, from which 9 were obtained from patients with metastatic prostate cancer. The expression of five examined genes had no correlation with PSA level and Gleason score. The expression of AMACR decreased in metastatic prostate cancer (P = 0.02). The expression of other genes showed no difference between metastatic and non-metastatic tumors (P > 0.1).
Genetic information combined with clinical data can be useful in risk assessment and treatment planning. Based on the results of the current study, the decreased expression of AMACR was a sign of poor prognosis.
Nephro-urology monthly. 2016 Jan 23*** epublish ***
Mohamadreza Nowroozi, Mohsen Ayati, Erfan Amini, Reza Mahdian, Behzad Yousefi, Amir Arbab, Mansour Jamali Zawarei, Hasan Niroomand, Hamidreza Ghorbani, Alireza Ghadian
Uro-Oncology Research Center (UORC), Tehran University of Medical Sciences, Tehran, Iran., Biotechnology Research Center, Molecular Medicine Department, Pasteur Institue of Iran, Tehran, Iran., Pathology Department, Tehran University of Medical Sciences, Tehran, Iran., AJA University of Medical Sciences, Tehran, Iran., Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran., Nephrology and Urology Research Center, Baqiyatallah University Medical Sciences, Tehran, Iran.